Geoffrey D Barnes, MD, MSc

 Geoff Barnes headshot
Associate Professor of Internal Medicine
Associate Chair, Department of Internal Medicine
Medical School and Medical Director
MPrOVe
Email:
[email protected]
Available to mentor
Geoffrey D Barnes, MD, MSc
Geoff Barnes headshot
Associate Professor
  • About
  • Links
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    Dr. Barnes is a cardiologist and vascular medicine specialist. His research focuses on developing, implementing, and evaluating antithrombotic stewardship efforts to improve the care of patients with thrombotic conditions and/or those who use anticoagulant medications. He serves as co-director for the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) and as co-director for the Michigan Program on Value Enhancement (MPrOVE). His research is funded by the NIH, AHRQ, and Blue Cross-Blue Shield of Michigan. He serves in leadership roles with several national and International organizations, including the Anticoagulation Forum, American College of Cardiology, and International Society on Thrombosis and Hemostasis. He also serves as the program director for the University of Michigan Vascular Medicine fellowship training program.

    Links
    • twitter

    Qualifications
    • Cardiovascular Medicine Fellowship
      University of Michigan, Internal Medicine/Cardiovascular Medicine, Ann Arbor, United States
      2011 - 2014
      Postdoctoral Fellowship
    • Vascular Medicine Fellowship
      University of Michigan, Internal Medicine/Cardiovascular Medicine, Ann Arbor, United States
      2013 - 2014
      Postdoctoral Fellowship
    • Internal Medicine Chief Residency
      University of Michigan, Internal Medicine, Ann Arbor, United States
      2010 - 2011
      Chief Resident
    • Internal Medicine Residency
      University of Michigan, Internal Medicine, Ann Arbor, United States
      2007 - 2010
      Residency
    • MS
      University of Michigan, Ann Arbor, Michigan, United States
      2014 - 2015
    • MD
      University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109, United States
      2003 - 2007
    • BS
      Washington University in St. Louis, St. Louis, MO, United States
      1999 - 2003

    Center Memberships
    • Center Member
      AI and Digital Health Innovation
    • Center Member
      Institute for Healthcare Policy and Innovation
    • Center Member
      Center for History, Humanities, Arts, Social Sciences and Ethics in Medicine
    • Center Member
      Samuel and Jean Frankel Cardiovascular Center

    Research Overview

    Anticoagulation therapy
    Venous Thromboembolism
    Implementation Science
    Quality Improvement
    Health systems engineering
    Shared decision-making

    Recent Publications

     See All Publications
    • Presentation
      Factor X or XI Inhibitors for Carotid Artery Disease
      Barnes G. 2026 Oct 3;
    • Presentation
      Overarching Changes in Acute PE Guideliens
      Barnes G. 2026 Oct 3;
    • Presentation
      Beyond Factor Xa: New Coagulation Targets for VTE Treatment
      Barnes G. 2026 Oct 3;
    • Presentation
      2026 Updates in VTE: Guidelines and Trials
      Barnes G. 2026 Oct 3;
    • Presentation
      Population-based DOAC Dashboards
      Barnes G. 2026 Oct 3;
    • Presentation
      2026 AHA/ACC Acute PE Guidelines: A Case-based approach
      Barnes G. 2026 Sep 22;
    • Presentation
      2026 AHA/ACC Acute PE Guidelines: A Case-based approach
      Barnes G. 2026 Sep 22;
    • Presentation
      2026 AHA/ACC Acute PE Guidelines: A Case-based approach
      Barnes G. 2026 Sep 22;

    Featured News & Stories

         pill bottle spilling yellow blue
    Health Lab

    Nearly 1 in 6 older adults take aspirin despite no history of heart disease

    Around 1 in 6 older adults take aspirin as their primary method of preventing cardiovascular disease, despite stricter guidelines. For some patients, the benefit of aspirin may not outweigh the risk of bleeding.
         prescription pad drawn
    Health Lab

    Reducing dose of popular blood thinners may limit risk of future bleeding

    For people taking the popular blood thinners rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis), after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.
         prescription pad blue yellow sketch
    Health Lab

    Risk of clots, stroke from incorrect blood thinner dosing reduced using online dashboard

    Doctors and pharmacists treating people with blood thinners can now reduce the rate of inappropriate dosing — as well as blood clots and strokes that can result from it — using an electronic patient management system.
         person at counter with medicine brown bottle and pills
    Health Lab

    Most blood thinner dosing problems happen after initial prescription

    More than two-thirds of those people take a type of blood thinner called a direct oral anticoagulant. These DOACs, such as rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis), are under- or over-prescribed in up to one in eight patents. These prescribing issues can have life-threatening consequences, and they most often occur after a provider writes the initial prescription, according to a study led by Michigan Medicine.